セルソース(株)の貸借残高情報
主市場 | 業種 | 証券コード/EDINET | 英名称 |
---|
東証PRM | 医薬品 | 4880/ - | - |
公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
---|
2021/08/13 | 日証協 | 131,350株 | +3.06% | 16,100株 | +42.41% | 141,980株 | -1.73% | 5,813株 | -46.18% |
2021/08/06 | 日証協 | 127,450株 | -29.86% | 11,305株 | -92.87% | 144,473株 | -15.38% | 10,801株 | -64.24% |
2021/07/30 | 日証協 | 181,700株 | +28.96% | 158,500株 | +109.38% | 170,728株 | +10.34% | 30,200株 | -17.04% |
2021/07/21 | 日証協 | 140,900株 | +27.63% | 75,700株 | +94.6% | 154,726株 | +13.58% | 36,402株 | +90.59% |
2021/07/16 | 日証協 | 110,400株 | +12.08% | 38,900株 | -18.96% | 136,226株 | +5.5% | 19,100株 | +32.63% |
2021/07/09 | 日証協 | 98,500株 | +23.28% | 48,000株 | +240.43% | 129,126株 | +12.16% | 14,401株 | +61.81% |
2021/07/02 | 日証協 | 79,900株 | -4.43% | 14,100株 | +28.18% | 115,125株 | -1.2% | 8,900株 | -8.73% |
2021/06/25 | 日証協 | 83,600株 | -6.38% | 11,000株 | -82.89% | 116,528株 | -1.14% | 9,751株 | -67.82% |
2021/06/18 | 日証協 | 89,300株 | -16.85% | 64,300株 | +127.21% | 117,877株 | -5.69% | 30,302株 | +79.3% |
2021/06/11 | 日証協 | 107,400株 | +6.02% | 28,300株 | -13.19% | 124,991株 | +2.63% | 16,900株 | -36.94% |
2021/06/04 | 日証協 | 101,300株 | +3.16% | 32,600株 | +27.84% | 121,791株 | +10.63% | 26,801株 | +95.61% |
2021/05/28 | 日証協 | 98,200株 | +0.1% | 25,500株 | +105.65% | 110,090株 | +5.26% | 13,701株 | +21.25% |
2021/05/21 | 日証協 | 98,100株 | -22.33% | 12,400株 | -37.37% | 104,590株 | -13.9% | 11,300株 | -1.91% |
2021/05/14 | 日証協 | 126,300株 | +2.02% | 19,800株 | -13.91% | 121,480株 | +1.18% | 11,520株 | +32.4% |
2021/05/07 | 日証協 | 123,800株 | +19.27% | 23,000株 | +161.36% | 120,069株 | +7.71% | 8,701株 | -32.55% |
2021/04/30 | 日証協 | 103,800株 | -24.45% | 8,800株 | -77.55% | 111,471株 | -5.99% | 12,900株 | -52.92% |
2021/04/23 | 日証協 | 137,400株 | +18.04% | 39,200株 | +55.56% | 118,571株 | +11.05% | 27,400株 | +78.83% |
2021/04/16 | 日証協 | 116,400株 | -12.68% | 25,200株 | +159.79% | 106,770株 | -10.07% | 15,322株 | -10.82% |
2021/04/09 | 日証協 | 133,300株 | -12.36% | 9,700株 | -67.01% | 118,730株 | -14.13% | 17,181株 | -14.1% |
※株式分割は考慮していませんのでご注意ください。
Page Top